Market News AIOpen the app

Capricor Therapeutics got a letter from the FDA saying their data for Deramiocel isn't good enough.

TrialRead the original at globenewswire.com
Bad for CAPR

The FDA said Capricor's application lacked enough proof that Deramiocel works and found clinical gaps. Capricor has cash for at least 12 months, but approval now faces a major setback.

CAPR · Capricor Therapeutics

AI read · Bad for CAPR

The AI's read

The FDA's findings leave Capricor needing to address evidence and clinical issues before Deramiocel can reach patients. The cash gives the company time to review the letter, but does not resolve those issues.

Get alerts for CAPR

Follow Capricor Therapeutics (CAPR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CAPR
Free on the App Store and Google Play, or on the web.